IL307649A - A combination that includes a specific HDAC6 inhibitor and at least one CTLA4 Checkpoint inhibitor - Google Patents
A combination that includes a specific HDAC6 inhibitor and at least one CTLA4 Checkpoint inhibitorInfo
- Publication number
- IL307649A IL307649A IL307649A IL30764923A IL307649A IL 307649 A IL307649 A IL 307649A IL 307649 A IL307649 A IL 307649A IL 30764923 A IL30764923 A IL 30764923A IL 307649 A IL307649 A IL 307649A
- Authority
- IL
- Israel
- Prior art keywords
- inhibitor
- combination
- ctla4 checkpoint
- specific hdac6
- ctla4
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT102021000009926A IT202100009926A1 (it) | 2021-04-20 | 2021-04-20 | Una combinazione comprendente un inibitore di hdac6 specifico e almeno un inibitore del checkpoint ctla4 |
| PCT/EP2022/060287 WO2022223543A1 (en) | 2021-04-20 | 2022-04-19 | A combination comprising a specific hdac6 inhibitor and at least one ctla4 checkpoint inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL307649A true IL307649A (en) | 2023-12-01 |
Family
ID=76808052
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL307649A IL307649A (en) | 2021-04-20 | 2022-04-19 | A combination that includes a specific HDAC6 inhibitor and at least one CTLA4 Checkpoint inhibitor |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20240207228A1 (enExample) |
| EP (1) | EP4326259A1 (enExample) |
| JP (1) | JP7902198B2 (enExample) |
| KR (1) | KR20230172001A (enExample) |
| CN (1) | CN117177745A (enExample) |
| AR (1) | AR125356A1 (enExample) |
| AU (1) | AU2022262199A1 (enExample) |
| BR (1) | BR112023021125A2 (enExample) |
| CA (1) | CA3213275A1 (enExample) |
| CL (1) | CL2023002894A1 (enExample) |
| CO (1) | CO2023013780A2 (enExample) |
| IL (1) | IL307649A (enExample) |
| IT (1) | IT202100009926A1 (enExample) |
| MX (1) | MX2023012030A (enExample) |
| PE (1) | PE20242078A1 (enExample) |
| TW (1) | TW202308609A (enExample) |
| WO (1) | WO2022223543A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119424649A (zh) * | 2024-02-29 | 2025-02-14 | 中山大学附属第一医院 | 假体周围感染治疗靶点及其应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190022203A1 (en) | 2016-01-11 | 2019-01-24 | Turnstone Limited Partnership | Oncolytic virus and checkpoint inhibitor combination therapy |
| IT201700041723A1 (it) * | 2017-04-14 | 2018-10-14 | Italfarmaco Spa | Nuovi inibitori selettivi di HDAC6 |
-
2021
- 2021-04-20 IT IT102021000009926A patent/IT202100009926A1/it unknown
-
2022
- 2022-03-25 TW TW111111338A patent/TW202308609A/zh unknown
- 2022-04-18 AR ARP220100959A patent/AR125356A1/es unknown
- 2022-04-19 IL IL307649A patent/IL307649A/en unknown
- 2022-04-19 PE PE2023002749A patent/PE20242078A1/es unknown
- 2022-04-19 EP EP22723425.9A patent/EP4326259A1/en active Pending
- 2022-04-19 MX MX2023012030A patent/MX2023012030A/es unknown
- 2022-04-19 BR BR112023021125A patent/BR112023021125A2/pt unknown
- 2022-04-19 CN CN202280027381.5A patent/CN117177745A/zh active Pending
- 2022-04-19 US US18/555,103 patent/US20240207228A1/en active Pending
- 2022-04-19 WO PCT/EP2022/060287 patent/WO2022223543A1/en not_active Ceased
- 2022-04-19 KR KR1020237039421A patent/KR20230172001A/ko active Pending
- 2022-04-19 JP JP2023564130A patent/JP7902198B2/ja active Active
- 2022-04-19 CA CA3213275A patent/CA3213275A1/en active Pending
- 2022-04-19 AU AU2022262199A patent/AU2022262199A1/en active Pending
-
2023
- 2023-09-28 CL CL2023002894A patent/CL2023002894A1/es unknown
- 2023-10-19 CO CONC2023/0013780A patent/CO2023013780A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN117177745A (zh) | 2023-12-05 |
| CL2023002894A1 (es) | 2024-03-15 |
| TW202308609A (zh) | 2023-03-01 |
| CO2023013780A2 (es) | 2023-11-10 |
| WO2022223543A1 (en) | 2022-10-27 |
| US20240207228A1 (en) | 2024-06-27 |
| IT202100009926A1 (it) | 2022-10-20 |
| MX2023012030A (es) | 2023-10-24 |
| BR112023021125A2 (pt) | 2023-12-12 |
| JP2024515100A (ja) | 2024-04-04 |
| PE20242078A1 (es) | 2024-10-18 |
| EP4326259A1 (en) | 2024-02-28 |
| AR125356A1 (es) | 2023-07-12 |
| CA3213275A1 (en) | 2022-10-27 |
| KR20230172001A (ko) | 2023-12-21 |
| AU2022262199A1 (en) | 2023-09-21 |
| JP7902198B2 (ja) | 2026-08-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL283598A (en) | Combined treatment with radio-immune conjugates and a checkpoint inhibitor | |
| IL308234A (en) | Monotherapy with an SHP2 inhibitor and its uses | |
| EP4347569A4 (en) | Combination therapy comprising a mat2a inhibitor and a type ii prmt inhibitor | |
| SG11202012241RA (en) | Erk inhibitor and use thereof | |
| IL307188A (en) | NLRP3 inhibitors | |
| PT3886798T (pt) | Composições de associação compreendendo um inibidor de beta-lactamase e suas utilizações | |
| FR2948672B1 (fr) | Materiau elastomere radio-attenuateur, gant multicouche de protection contre les rayonnements ionisants et leurs utilisations | |
| IL288716B2 (en) | Combination therapy that combines an anti-CD19 antibody drug with a PI3K inhibitor or a secondary factor | |
| PL3792192T3 (pl) | Układ torebek opakowaniowych oraz sposób wytwarzania układu torebek opakowaniowych i obsługi układu torebek opakowaniowych | |
| IL290003A (en) | A matrix that adheres to the tissue and its use | |
| PL3847011T3 (pl) | Laminowana tuba i jej wdrożenia | |
| ZA202202318B (en) | Goods protection insert and uses thereof | |
| SI4244208T1 (sl) | Zaviralec magl | |
| IL309243A (en) | Radioimmunoconjugates and combination therapy with barrier surveillance | |
| EP3947529C0 (en) | GELATIN AND ITS USES | |
| IL311588A (en) | LPXC inhibitors and their uses | |
| HK40100711A (en) | A combination comprising a specific hdac6 inhibitor and at least one ctla4 checkpoint inhibitor | |
| PT3712588T (pt) | Método para detetar danos provocados por fadiga numa unidade hidráulica e a respetiva unidade hidráulica | |
| IL291396A (en) | mll1 inhibitors and anticancer drugs | |
| GB2588174B (en) | A jig and use thereof | |
| IL314530A (en) | NTSR1-targeted radiopharmaceuticals and DNA damage response inhibitor combination therapy | |
| GB201900929D0 (en) | Nf-kappa b inhibitors | |
| PT4337652T (pt) | Inibidores do nlrp3 | |
| HK40109325A (en) | Radioimmunoconjugates and checkpoint inhibitor combination therapy | |
| HK40118666A (en) | Psma-targeted radiopharmaceuticals and checkpoint inhibitor combination therapy |